As had long been expected, Novartis has announced plans to hive off its generics business, Sandoz, creating a new publicly-traded company. 25 August 2022
Competition for AstraZeneca’s Soliris (eculizumab) is stepping closer to the market, with developer Amgen, a Californian company, announcing positive trial resu 24 August 2022
The Pharmaceutical Research and Manufacturers of America (PhRMA) is to oppose what it calls “flawed price-setting proposals,” arguing instead for changes to the 20 July 2022
A proposed biosimilar to Soliris (eculizumab) has shown clinical equivalence in efficacy and safety in people with paroxysmal nocturnal hemoglobinuria (PNH). 12 July 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.